A preparation method of pyrroloquinoxaline
By reacting the compound of formula I and the compound of formula II in a solvent in a palladium catalyst and a hydrogen source, the problem of harsh reaction conditions and the use of toxic reagents in the prior art is solved, and the problem of harsh reaction conditions of the phenylpyrroloquinoxaline synthesis method is achieved. Efficient and environmentally friendly synthesis process.
Patent Information
- Application Number
- CN202211283173.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-10-19
AI Technical Summary
In the prior art, the synthesis method of phenylpyrroloquinoxaline has problems such as harsh reaction conditions, long reaction steps, and the need to use equivalent toxic and harmful reagents, and lacks a more effective, green and environmentally friendly synthesis method.
Pyrroloquinoxaline is obtained by reacting the compound of formula I and the compound of formula II in a solvent in a palladium catalyst and a hydrogen source. The reaction conditions of this method are mild, have good selectivity, high product yield and easy separation of products.
The efficient synthesis of pyrroloquinoxaline is achieved, and the synthesis steps are simplified. The raw materials used are non-toxic and inexpensive, with the advantages of good functional group compatibility, high atomic economy and high yield.
Smart Images

Figure CN115677708B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for preparing pyrroloquinoxaline. Background Art
[0002] Phenylpyrroloquinoxaline and its derivatives are an important class of nitrogen-containing benzopyrrole heterocyclic compounds with a wide range of biological activities. They can be used as anticancer and antitumor agents, HIV-1 reverse transcriptase inhibitors, and quinoxaline derivatives also have inhibitory effects on many pathogenic microorganisms. Quinoxaline derivatives also have good herbicidal activity, among which the most representative is quizalofop-p-ethyl, which has the characteristics of high safety and good rain resistance. In addition, quinoxaline derivatives are also widely used in plant growth regulators, anti-inflammatory, bactericidal, insecticidal and photoelectric materials.
[0003] In view of the problems of the previously reported synthesis methods of phenylpyrrolo[1,2-a]quinoxaline, such as harsh reaction conditions, long reaction steps, and the need to use equivalent amounts of toxic and hazardous reagents, it is very necessary to develop a more efficient, green, and environmentally friendly method for synthesizing pyrrolo[1,2-a]quinoxaline. Summary of the invention
[0004] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention provides a method for preparing pyrroloquinoxaline, which has the advantages of mild reaction conditions, good reaction selectivity, high product yield, and easy product separation.
[0005] A method for preparing pyrroloquinoxaline according to the first aspect of the present invention comprises the following steps:
[0006] In a solvent, the compound of formula I and the compound of formula II are reacted in the presence of a palladium catalyst and a hydrogen source to obtain a compound of formula III:
[0007] The structural formulas of the compounds of formula I, II and III are as follows:
[0008]
[0009] Wherein, R1 is selected from H, C 1~12 One of the alkyl, aromatic or heteroaromatic groups;
[0010] R2 is selected from H, C 1~12 Alkyl, C 1~12 One of alkoxy, amino, halogen, aromatic or heteroaromatic groups;
[0011] R3 is selected from H or C 1~12 One of the alkyl groups;
[0012] The hydrogen source is a mixture of a first hydrogen source and a second hydrogen source, and the first hydrogen source is formic acid.
[0013] A method for preparing pyrroloquinoxaline according to an embodiment of the present invention has at least the following beneficial effects:
[0014] The mechanism of the present invention is as follows: the compound of formula I and the compound of formula II are first selectively reduced to aminopyrrole and imine, respectively, and then the amino group attacks the imine to remove a molecule of ammonia, and finally the palladium catalyst is used for CH activation and ring closure to obtain the compound of formula III.
[0015] The present invention uses a compound of formula I and a compound of formula II as raw materials to prepare pyrroloquinoxaline through a one-step method. Not only are the synthetic steps simple, the raw materials are non-toxic, cheap and easily available, but the synthetic method also has the advantages of good functional group compatibility, high atom economy and high yield.
[0016] According to some embodiments of the present invention, the R1 is selected from at least one of a cyclopropane group, a pyridyl group, and a substituted or unsubstituted phenyl group.
[0017] According to some embodiments of the present invention, R2 is selected from at least one of methyl, methoxy, ethoxy, amino, pyridyl, and halogen.
[0018] According to some embodiments of the present invention, the second hydrogen source includes at least one of sodium formate, potassium formate, ammonium formate, methanol, benzyl alcohol, isopropanol, phenylsilane, borane or sodium borohydride.
[0019] According to some embodiments of the present invention, the palladium catalyst further includes a carrier-supported palladium catalyst.
[0020] According to some embodiments of the present invention, the carrier includes at least one of aluminum oxide or silicon dioxide.
[0021] According to some embodiments of the present invention, the palladium catalyst includes at least one of alumina-supported nano-palladium, silica-supported nano-palladium, palladium hydroxide and palladium acetate.
[0022] According to some embodiments of the present invention, the molar ratio of the compound of formula I to the compound of formula II is 1:1-10.
[0023] According to some embodiments of the present invention, the molar ratio of the palladium catalyst to the compound of formula I is 0.02-0.08:1.
[0024] According to some embodiments of the present invention, the solvent includes an organic solvent or an inorganic solvent.
[0025] According to some embodiments of the present invention, the organic solvent includes at least one of a nitrile solvent, an amide solvent, an ether solvent, a pyridine solvent, an alcohol solvent and an aromatic hydrocarbon solvent.
[0026] According to some embodiments of the present invention, the nitrile solvent includes acetonitrile.
[0027] According to some embodiments of the present invention, the amide solvent includes at least one of N-methylformamide, formamide, N-ethylformamide and N,N-dimethylformamide.
[0028] According to some embodiments of the present invention, the ether solvent includes tetrahydrofuran.
[0029] According to some embodiments of the present invention, the pyridine-based solvent includes pyridine.
[0030] According to some embodiments of the present invention, the alcohol solvent includes at least one of tert-amyl alcohol, isopropanol, isobutanol and methanol.
[0031] According to some embodiments of the present invention, the aromatic hydrocarbon solvent includes at least one of toluene and p-xylene.
[0032] According to some embodiments of the present invention, the inorganic solvent comprises water.
[0033] According to some embodiments of the present invention, the volume ratio of the solvent to the compound of formula I is 1-2:1.
[0034] According to some embodiments of the present invention, the preparation method further comprises the following steps: after the reaction is completed, the solvent is removed and then purified.
[0035] According to some embodiments of the present invention, the purification method is column chromatography.
[0036] According to some embodiments of the present invention, the stationary phase used in the column chromatography is silica gel, and the eluent used is a mixed solvent of petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is petroleum ether:ethyl acetate=(0.5-100):1.
[0037] Definitions and general terms
[0038] "Aromatic group" means an all-carbon monocyclic or fused polycyclic group having a completely conjugated π-electron system. 6~20 The term "aryl" refers to an all-carbon monocyclic or condensed polycyclic group of 6 to 20 carbon atoms; for example, benzene, naphthalene, indene, fluorene, etc.
[0039] "Heteroaromatic" means a monocyclic or fused ring radical of ring atoms containing one, two, three or four ring heteroatoms selected from N, O or S, the remaining ring atoms being C, and otherwise having a completely conjugated pi electron system.
[0040] Heteroaryl refers to:
[0041] 5-8 membered monocyclic aromatic hydrocarbons containing one or more heteroatoms selected from N, O and S, such as 1-4 heteroatoms, in some embodiments, 1-3 heteroatoms, and the other atoms in the ring are carbon atoms;
[0042] 8-12 membered bicyclic aromatic hydrocarbons containing one or more heteroatoms selected from N, O and S, such as 1-4 heteroatoms, in some embodiments, 1-3 heteroatoms, and the other atoms on the ring are carbon atoms; wherein at least one ring is an aromatic ring; and 11-14 membered tricyclic aromatic hydrocarbons containing one or more heteroatoms selected from N, O and S, such as 1-4 heteroatoms, in some embodiments, 1-3 heteroatoms, and the other atoms on the ring are carbon atoms; wherein at least one ring is an aromatic ring.
[0043] For example, the heteroaryl group includes a 5-6 membered heteroaromatic ring and a 5-6 membered cycloalkyl group. For such bicyclic heteroaromatic groups, only one of which contains one or more heteroatoms, the point of attachment is on the heteroaromatic ring.
[0044] Examples of heteroaryl groups include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, triazole, pyrimidine, pyridine, pyridone, imididine, pyrazine, pyridazine, indole, azaindole, benzimidazole, benzotriazole, indoline, indolone, quinoline, isoquinoline, quinazoline, thienopyridine, thienopyrimidine, etc. Preferred examples of such groups are pyrrolyl, pyrazolyl, imidazolyl, triazolyl, furanyl, oxazolyl, thienyl, thiazolyl, benzimidazolyl, benzotriazole. One or all of the hydrogen atoms in the heteroaryl group may be substituted by hydrogen, hydroxy, nitro, cyano, oxo, lower alkyl, lower alkoxy, lower cycloalkyl, lower heteroalicyclic, lower haloalkoxy, alkylthio, halogen, lower haloalkyl, lower hydroxyalkyl, lower cycloalkylalkylene, lower heteroalicyclicalkylene, aryl, heteroaryl, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino.
[0045] “C 1~12 "Alkoxy" represents -O-(unsubstituted alkyl) and -O(unsubstituted cycloalkyl), with a total carbon atom count of 1 to 12. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0046] “C 1~12 "Alkyl" means an alkyl group having 1 to 12 carbon atoms, including C 1~12 Straight chain alkyl, C 1~12 The branched alkyl and C 3~12The cycloalkyl group may be, for example, a straight-chain alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, a branched-chain alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, or a cycloalkyl group having 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, cyclopropyl, methylcyclopropyl, ethylcyclopropyl, cyclopentyl, methylcyclopentyl, cyclohexyl, etc.
[0047] The "halogen" refers to at least one of fluorine, chlorine, bromine or iodine.
[0048] Other features and advantages of the present invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0050] Figure 1 is the hydrogen spectrum of the product prepared in Example 1;
[0051] Figure 2 The carbon spectrum of the product prepared in Example 1;
[0052] Figure 3 is the hydrogen spectrum of the product prepared in Example 2;
[0053] Figure 4 The carbon spectrum of the product prepared in Example 2;
[0054] Figure 5 is the hydrogen spectrum of the product prepared in Example 3;
[0055] Figure 6 The carbon spectrum of the product prepared in Example 3;
[0056] Figure 7 is the hydrogen spectrum of the product prepared in Example 4;
[0057] Figure 8 The carbon spectrum of the product prepared in Example 4;
[0058] Fig. 9 is the hydrogen spectrum of the product prepared in Example 5;
[0059] Fig.10 The carbon spectrum of the product prepared in Example 5;
[0060] Fig.11is the hydrogen spectrum of the product prepared in Example 6;
[0061] Fig.12 The carbon spectrum of the product prepared in Example 6;
[0062] Fig.13 is the hydrogen spectrum of the product prepared in Example 7;
[0063] Fig.14 The carbon spectrum of the product prepared in Example 7;
[0064] Fig.15 is the hydrogen spectrum of the product prepared in Example 8;
[0065] Fig.16 The carbon spectrum of the product prepared in Example 8;
[0066] Fig.17 is the hydrogen spectrum of the product prepared in Example 9;
[0067] Fig.18 The carbon spectrum of the product prepared in Example 9;
[0068] Fig.19 is the hydrogen spectrum of the product prepared in Example 10;
[0069] Fig. 20 The carbon spectrum of the product prepared in Example 10;
[0070] Fig.21 is the hydrogen spectrum of the product prepared in Example 11;
[0071] Fig. 22 This is the carbon spectrum of the product prepared in Example 11. DETAILED DESCRIPTION
[0072] The following are specific embodiments of the present invention, and the technical solutions of the present invention are further described in conjunction with the embodiments, but the present invention is not limited to these embodiments.
[0073] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0074] Example 1
[0075] Example 1 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0076]
[0077] 0.25 mmol 2-nitrophenylpyrrole, 2.5 mmol benzonitrile, 1 mmol formic acid, 1 mmol sodium formate, 60 mg aluminum palladium trioxide and 1 ml water were added to a schlenk tube. After stirring and reacting at 100° C. under nitrogen for 16 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=10:1, v / v). The yield of the target product was 85%.
[0078] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Figure 1 and Figure 2 The structural characterization data are as follows:
[0079] 1 H NMR (400MHz, CDCl3): δ8.05 (dd, J=8.0, 1.6Hz, 1H), 7.99-8.02 (m, 3H), 7.90 (dd, J=8.0, 1.4Hz, 1H ),7.51-7.57(m,4H),7.45-7.49(m,1H),7.00(dd,J=4.1,1.4Hz,1H),6.91(dd,J=4.0,2.6Hz,1H);
[0080] 13 C{1H}NMR (100MHz, CDCl3): δ154.5,138.5,136.3,130.3,130.0,128.7,128.7,127.6,127.3,125.5,125.4,114.8,114.1,113.7,108.9;
[0081] MS (EI, m / z): 244.1 [M] + .
[0082] Example 2
[0083] Example 2 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0084]
[0085] 0.25 mmol 2-nitrophenylpyrrole, 2.5 mmol benzonitrile, 1 mmol formic acid, 1 mmol ammonium formate, 60 mg palladium carbon catalyst and 1 ml toluene were added to a schlenk tube. After stirring and reacting at 100° C. under nitrogen for 14 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=8:1, v / v). The yield of the target product was 79%.
[0086] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Figure 3 and Figure 4 The structural characterization data are as follows:
[0087] 1 H NMR (500MHz, CDCl3): δ8.06(dd,J=7.9,1.6Hz,1H),7.99(dd,J=2.8,1.3Hz,1H),7.92(d,J=8.1Hz,2H),7.87(dd,J=8.1,1.4Hz,1H),7.50(ddd,J =8.3,7.3,1.6Hz,1H),7.45(td,J=7.6,1.4Hz,1H),7.36(d,J=7.9Hz,2H),7.01(dd,J=4.1,1.3Hz,1H),6.89(dd,J=4.0,2.7Hz,1H),2.46(s,3H);
[0088] 13 C{ 1 H}NMR (126MHz, CDCl3): δ154.3,140.1,136.1,135.5,130.1,129.3,128.6,127.3,127.1,125.4,125.3,114.6,114.0,113.6,108.92,21.52.
[0089] MS (EI, m / z): 259.1 [M] + .
[0090] Example 3
[0091] Example 3 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0092]
[0093] 0.25 mmol 2-nitrophenylpyrrole, 2.5 mmol p-methoxybenzonitrile, 1 mmol formic acid, 1 mmol potassium formate, 60 mg silica palladium catalyst and 1 ml p-xylene were added to a schlenk tube. After stirring and reacting for 16 hours at 110° C. under nitrogen, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=10:1, v / v). The yield of the target product was 79%.
[0094] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Figure 5 and Figure 6 The structural characterization data are as follows:
[0095] 1 H NMR (500MHz, CDCl3): δ8.07(dd,J=8.0,1.6Hz,1H),8.02–7.98(m,3H),7.86(dd,J=8.1,1.4Hz,1H),7.52 –7.42(m,2H),7.09–7.05(m,2H),7.03(dd,J=4.0,1.3Hz,1H),6.90(dd,J=4.0,2.7Hz,1H),3.90(s,3H);
[0096] 13 C{ 1 H}NMR (126MHz, CDCl3): δ134.9,134.7,133.7,133.4,130.0,129.0,126.4,126.3 ,5.6,124.8,119.3,116.0,114.6,114.3,110.0,102.9,,52.3,40.7,33.0,25.9;
[0097] MS (EI, m / z): 275.2 [M] + .
[0098] Example 4
[0099] Example 4 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0100]
[0101] 0.25 mmol 2-nitrophenylpyrrole, 2.5 mmol m-methoxybenzonitrile, 1 mmol formic acid, 1 mmol sodium formate, 60 mg palladium acetate catalyst and 1 ml methanol were added to a schlenk tube. After stirring and reacting at 90° C. under nitrogen for 10 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=6:1, v / v). The yield of the target product was 81%.
[0102] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Figure 7 and Figure 8 The structural characterization data are as follows:
[0103] 1 H NMR (500MHz, CDCl3): δ8.10 (dd, J=8.0, 1.5Hz, 1H), 8.01 (dd, J=2.7, 1.3Hz, 1H), 7.88 (dd, J=8.2, 1.4Hz, 1H), 7.59 (dt, J=7.6, 1.3Hz, 1H), 7. 56–7.51(m,2H),7.49–7.43(m,2H),7.08(ddd,J=8.2,2.7,1.0Hz,1H),7.04(dd,J=4.1,1.3Hz,1H),6.91(dd,J=4.1,2.7Hz,1H),3.91(s,3H);
[0104] 13 C{ 1 H}NMR(126MHz, CDCl3)::δ159.8,154.1,135.8,130.0,129.6,127.6,127.1,125.4,125.3,121.2,116.2,115.0,114.2,113.8,113.7,109.3,55.5;
[0105] MS (EI, m / z): 275.1 [M] + .
[0106] Example 5
[0107] Example 5 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0108]
[0109] 0.25 mmol 2-nitrophenylpyrrole, 2.5 mmol o-methoxybenzonitrile, 1 mmol isopropanol, 1 mmol formic acid, 60 mg palladium hydroxide catalyst and 1 ml ethanol were added to a schlenk tube. After stirring and reacting for 11 hours at 80° C. under nitrogen, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=5:1, v / v). The yield of the target product was 68%.
[0110] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Fig. 9 and Fig.10 The structural characterization data are as follows:
[0111] 1 H NMR (500MHz, CDCl3): δ8.07 (dd, J=8.0, 1.6Hz, 1H), 8.02–7.97 (m, 3H), 7.86 (dd, J=8.1, 1.4Hz, 1H), 7.47 (dtd, J= 24.6,7.2,1.5Hz,2H),7.10–7.05(m,2H),7.03(dd,J=4.0,1.3Hz,1H),6.90(dd,J=4.0,2.7Hz,1H),3.90(s,3H);
[0112] 13 C{ 1 H}NMR (126MHz, CDCl3): δ161.2,153.8,135.9,130.6,130.2,129.8,127.3,127.1,125.3,125.3,114.8,114.1,114.0,113.6,109.1,55.5;
[0113] MS (EI, m / z): 275.1 [M] + .
[0114] Example 6
[0115] Example 6 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0116]
[0117] 0.25 mmol 2-nitrophenylpyrrole, 2.5 mmol dimethylbenzonitrile, 1 mmol formic acid, 1 mmol methanol, 60 mg palladium carbon catalyst and 1 ml DMSO were added to a schlenk tube. After stirring and reacting at 90° C. under nitrogen for 12 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=8:1, v / v). The yield of the target product was 61%.
[0118] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Fig.11 and Fig.12 As shown, the structural characterization data are as follows:
[0119] 1 H NMR (500MHz,CDCl3):δ8
[0120] .10–8.05(m,1H),8.05–8.00(m,2H),7.97(dd,J=2.7,1.3Hz,1H),7.88–7.83(m,1H ),7.51–7.42(m,2H),7.10(dd,J=4.0,1.3Hz,1H),6.92–6.85(m,3H),3.08(s,6H);
[0121] 13 C{ 1 H}NMR126 MHz, CDCl3): δ154.2,151.7,136.4,129.9,129.7,126.9,126.7,126.1,125.4,125.1,114.4,113.8,113.6,111.9,108.8,40.4;
[0122] MS (EI, m / z): 287.1 [M] + .
[0123] Example 7
[0124] Example 7 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0125]
[0126] 0.25 mmol 4-methyl-2-nitrophenylpyrrole, 2.5 mmol 3-nitrilepyridine, 1 mmol formic acid, 1 mmol sodium formate, 60 mg palladium catalyst and 2 ml DMF were added to a schlenk tube. After stirring and reacting at 90° C. under nitrogen for 18 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=6:1, v / v). The yield of the target product was 62%.
[0127] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Fig.13 and Fig.14 The structural characterization data are as follows:
[0128] 1 H NMR (500MHz, CDCl3): δ8.49(d,J=4.6Hz,1H),8.44(s,1H),8.27(d,J=7.4Hz,1H),7.99(d,J=8 .7Hz,2H),7.40(dd,J=8.0,4.6Hz,1H),7.06(d,J=8.6Hz,3H),6.92–6.89(m,1H),3.89(s,3H);
[0129] 13 C{ 1 H}NMR (126MHz, CDCl3): δ161.3,154.6,146.3,139.2,137.0,131.1,130.4,130.2,126.7,121.6,116.0,114.5,114.1,110.4,55.5;
[0130] MS (EI, m / z): 259.1 [M] + .
[0131] Example 8
[0132] Example 8 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0133]
[0134] 0.25 mmol N-methyl-2-phenyl(2-nitro)pyrrole, 2.5 mmol benzonitrile, 1 mmol sodium borohydride, 1 mmol formic acid, 60 mg aluminum trioxide palladium catalyst and 1 ml water were added to a schlenk tube. After stirring and reacting at 90° C. under nitrogen for 12 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=7:1, v / v). The yield of the target product was 53%.
[0135] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Fig.15 and Fig.16 The structural characterization data are as follows:
[0136] 1 H NMR (500MHz, CDCl3): δ8.38 (dd, J=22.4, 8.7Hz, 2H), 8.05 (d, J=7.0Hz, 2H), 7.64 (t, J=8.3Hz, 1H ),7.56(t,J=7.4Hz,3H),7.50(s,1H),7.09(d,J=3.1Hz,1H),6.83(d,J=3.1Hz,1H),4.27(s,3H);
[0137] 13 C{1H}NMR (126MHz, CDCl3): δ154.7,134.9,130.5,129.8,129.2,128.9,128.6,126.4,125.5,90.4,90.2,118.3,103.2,38.2;
[0138] MS (EI, m / z): 259.1 [M] + .
[0139] Example 9
[0140] Example 9 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0141]
[0142] 0.25 mmol of 4-n-propyl-2-nitrophenylpyrrole, 2.5 mmol of cyclohexanecarbonitrile, 1 mmol of phenylsilane, 1 mmol of formic acid, 60 mg of palladium hydroxide catalyst and 1 ml of tetrahydrofuran were added to a schlenk tube. After stirring and reacting for 15 hours at 100° C. under nitrogen, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=10:1, v / v). The yield of the target product was 57%.
[0143] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Fig.17 and Fig.18 The structural characterization data are as follows:
[0144] 1 H NMR (500MHz, CDCl3): δ7.96 (d, J=7.9Hz, 1H), 7.91–7.88 (m, 1H), 7.81 (dd, J=8.0, 1.5Hz, 1H), 7.47–7.40 (m, 2H), 6.9 5(d,J=4.0Hz,1H),,6.84(dd,J=4.0,2.7Hz,1H),3.14(tt,J=11.8,3.4Hz,1H),2.02–1.82(m,6H),1.52–1.33(m,4H);
[0145] 13 C{1H}NMR (126MHz, CDCl3): δ161.1,129.6,127.2,126.8,125.6,125.0,114.1,113.5,113.3,105.9,43.6,31.3,26.6,26.1;
[0146] MS (EI, m / z): 250.1 [M] + .
[0147] Example 10
[0148] Example 10 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0149]
[0150] 0.25 mmol 5-methoxyphenylpyrrole, 2.5 mmol acetonitrile, 1 mmol isopropanol, 1 mmol formic acid, 60 mg palladium carbon catalyst and 1 ml formamide were added to a schlenk tube. After stirring and reacting at 95° C. under nitrogen for 14 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=6:1, v / v). The yield of the target product was 67%.
[0151] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Fig.19 and Fig. 20 The structural characterization data are as follows:
[0152] 1 H NMR (500MHz, CDCl3): δ7.85–7.81(m,1H),7.68(dd,J=2.5,1.1Hz,1H),7.60–7.57(m,1H),7.30(dd d,J=10.0,3.9,2.9Hz,2H),6.74(dd,J=3.9,1.1Hz,1H),6.69(dd,J=3.8,2.8Hz,1H),2.63(s,3H);
[0153] 13 C{1H}NMR (126MHz, CDCl3): δ153.4,135.8,129.1,127.1,126.7,126.1,124.9,114.1,113.5,113.3,106.4,21.9;
[0154] MS (EI, m / z): 182.1 [M] + .
[0155] Embodiment 11
[0156] Example 11 provides a method for preparing pyrroloquinoxaline, the structural formula and preparation method are as follows:
[0157]
[0158] 0.25 mmol N-methyl-2-phenyl(2-nitro)pyrrole, 2.5 mmol benzonitrile, 1 mmol sodium borohydride, 1 mmol formic acid, 60 mg aluminum trioxide palladium catalyst and 1 ml water were added to a schlenk tube. After stirring and reacting at 90° C. under nitrogen for 12 hours, heating and stirring were stopped, and the mixture was cooled to room temperature. The solvent was removed by rotary evaporation under reduced pressure, and then separated and purified by column chromatography to obtain the target product. The stationary phase of the column chromatography used was silica gel, and the eluent was a mixed solvent of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=7:1, v / v). The yield of the target product was 53%.
[0159] The hydrogen spectrum and carbon spectrum of the obtained product are as follows: Fig.21 and Fig. 22 The structural characterization data are as follows:
[0160] 1 H NMR (500MHz, CDCl3): δ7.95(d,J=9.6Hz,1H),7.91(d,J=4.1Hz,1H),7.82(d,J=9.5Hz,1H),7.50–7.39(m,2H),6.93(d,J= 5.3Hz,1H),6.85(d,J=6.7Hz,1H),3.04(d,J=16.0Hz,2H),1.94–1.84(m,2H),1.55–1.46(m,2H),0.98(t,J=7.4Hz,,3H);
[0161] 13 C{1H}NMR(126MHz, CDCl3)::δ157.6,135.7,129.2,127.2,126.9,125.9,125.2,114.4,113.6,113.6,106.7,106.6,35.6,30.8,22..9,14.0.
[0162] MS (EI, m / z): 244.1 [M] + .
[0163] Comparative Example 1
[0164] Comparative Example 1 provides a method for preparing pyrroloquinoxaline, which is the same as that of Example 1, except that only formic acid is added as the hydrogen source; and the yield of the target product is only 30%.
[0165] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge scope of ordinary technicians in the relevant technical field without departing from the purpose of the present invention.
Claims
1. A method for preparing pyrroloquinoxaline, characterized in that: The steps include: In a solvent, the compound of formula I and the compound of formula II are reacted in the presence of a palladium catalyst and a hydrogen source to obtain a compound of formula III: The structural formulas of the compounds of formula I, II and III are as follows: Wherein, R1 is selected from H, C 1~12 One of alkyl, phenyl, p-methylphenyl, p-methoxyphenyl, m-methoxyphenyl, o-methoxyphenyl, 4-N,N-dimethylphenyl, and 3-pyridyl; R2 is selected from one of H, methyl, methoxy, ethoxy, amino, pyridyl, and halogen; R3 is selected from H or C 1~12 One of the alkyl groups; The hydrogen source is a mixture of a first hydrogen source and a second hydrogen source, wherein the first hydrogen source is formic acid; The second hydrogen source is selected from at least one of sodium formate, potassium formate, ammonium formate, methanol, benzyl alcohol, isopropanol, phenylsilane, borane or sodium borohydride.
2. The method for preparing pyrroloquinoxaline according to claim 1, characterized in that: The palladium catalyst is selected from a carrier-supported palladium catalyst.
3. The method for preparing pyrroloquinoxaline according to claim 1, characterized in that: The molar ratio of the compound of formula I to the compound of formula II is 1:1-10.
4. The method for preparing pyrroloquinoxaline according to claim 1, characterized in that: The molar ratio of the palladium catalyst to the compound of formula I is 0.02-0.08:
1.
5. The method for preparing pyrroloquinoxaline according to claim 1, characterized in that: The solvent is selected from an organic solvent or an inorganic solvent.
6. The method for preparing pyrroloquinoxaline according to claim 1, characterized in that: The reaction temperature is 25-130°C.
7. The method for preparing pyrroloquinoxaline according to claim 1, characterized in that: The reaction time is 1 to 24 hours.
Citation Information
Patent Citations
Antibiotic compounds
CN101400674A
Novel compound and its use as pde10 inhibitor
JP2014231475A
